(KYMR) Kymera Therapeutics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5015751044
Stock: Drug Discovery, Protein Degradation, Small Molecules, Clinical Trials
Total Rating 43
Risk 83
Buy Signal -0.11
| Risk 5d forecast | |
|---|---|
| Volatility | 61.8% |
| Relative Tail Risk | -9.35% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.47 |
| Alpha | 138.32 |
| Character TTM | |
|---|---|
| Beta | 1.667 |
| Beta Downside | 0.379 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.59% |
| CAGR/Max DD | 0.61 |
EPS (Earnings per Share)
Revenue
Description: KYMR Kymera Therapeutics March 05, 2026
Kymera Therapeutics Inc. (NASDAQ: KYMR) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics. Their core technology utilizes the bodys natural protein degradation system to target disease-causing proteins. This approach is a novel method within drug discovery.
The companys pipeline includes an IRAK4 program in Phase II clinical trials for immunology-inflammation diseases like hidradenitis suppurativa and atopic dermatitis. They are also developing programs for STAT6 in allergic/atopic diseases and TYK2 for autoimmune and inflammatory conditions. The biopharmaceutical sector is characterized by lengthy and expensive drug development cycles.
Kymera has a strategic alliance with Sanofi S.A. for IRAK4 drug candidates, excluding oncology and immuno-oncology applications. This partnership provides external funding and validation for their research. Headquartered in Watertown, Massachusetts, the company was incorporated in 2015.
For more detailed financial and operational data, ValueRay offers in-depth company profiles.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -311.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.13 > 0.02 and ΔFCF/TA 7.75 > 1.0 |
| NWC/Revenue: 2010 % < 20% (prev 940.1%; Δ 1070 % < -1%) |
| CFO/TA -0.13 > 3% & CFO -232.9m > Net Income -311.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (84.4m) vs 12m ago 5.50% < -2% |
| Gross Margin: 94.78% > 18% (prev 0.84%; Δ 9393 % > 0.5%) |
| Asset Turnover: 2.88% > 50% (prev 4.81%; Δ -1.93% > 0%) |
| Interest Coverage Ratio: -897.3 > 6 (EBITDA TTM -302.4m / Interest Expense TTM 347.0k) |
Altman Z'' -7.41
| A: 0.45 (Total Current Assets 871.2m - Total Current Liabilities 83.2m) / Total Assets 1.74b |
| B: -0.61 (Retained Earnings -1.07b / Total Assets 1.74b) |
| C: -0.23 (EBIT TTM -311.4m / Avg Total Assets 1.36b) |
| D: -6.52 (Book Value of Equity -1.06b / Total Liabilities 163.1m) |
| Altman-Z'' Score: -7.41 = D |
Beneish M
| DSRI: none (Receivables none/947.0k, Revenue 39.2m/47.1m) |
| GMI: 0.89 (GM 94.78% / 84.34%) |
| AQI: 1.19 (AQ_t 0.45 / AQ_t-1 0.38) |
| SGI: 0.83 (Revenue 39.2m / 47.1m) |
| TATA: -0.05 (NI -311.4m - CFO -232.9m) / TA 1.74b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of KYMR shares?
As of March 08, 2026, the stock is trading at USD 83.49 with a total of 455,416 shares traded.
Over the past week, the price has changed by -8.60%, over one month by +4.90%, over three months by -11.46% and over the past year by +156.58%.
Over the past week, the price has changed by -8.60%, over one month by +4.90%, over three months by -11.46% and over the past year by +156.58%.
Is KYMR a buy, sell or hold?
Kymera Therapeutics has received a consensus analysts rating of 4.55.
Therefore, it is recommended to buy KYMR.
- StrongBuy: 14
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the KYMR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 119.8 | 43.5% |
| Analysts Target Price | 119.8 | 43.5% |
KYMR Fundamental Data Overview March 05, 2026
P/S = 176.1729
P/B = 7.6173
Revenue TTM = 39.2m USD
EBIT TTM = -311.4m USD
EBITDA TTM = -302.4m USD
Long Term Debt = 68.5m USD (estimated: total debt 82.3m - short term 13.8m)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 82.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -274.8m USD (from netDebt column, last quarter)
Enterprise Value = 6.14b USD (6.91b + Debt 82.3m - CCE 848.3m)
Interest Coverage Ratio = -897.3 (Ebit TTM -311.4m / Interest Expense TTM 347.0k)
EV/FCF = -26.21x (Enterprise Value 6.14b / FCF TTM -234.3m)
FCF Yield = -3.82% (FCF TTM -234.3m / Enterprise Value 6.14b)
FCF Margin = -597.8% (FCF TTM -234.3m / Revenue TTM 39.2m)
Net Margin = -794.4% (Net Income TTM -311.4m / Revenue TTM 39.2m)
Gross Margin = 94.78% ((Revenue TTM 39.2m - Cost of Revenue TTM 2.05m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.52 (Enterprise Value 6.14b / Total Assets 1.74b)
Interest Expense / Debt = 0.08% (Interest Expense 69.0k / Debt 82.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -246.0m (EBIT -311.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.47 (Total Current Assets 871.2m / Total Current Liabilities 83.2m)
Debt / Equity = 0.05 (Debt 82.3m / totalStockholderEquity, last quarter 1.58b)
Debt / EBITDA = 0.91 (negative EBITDA) (Net Debt -274.8m / EBITDA -302.4m)
Debt / FCF = 1.17 (negative FCF - burning cash) (Net Debt -274.8m / FCF TTM -234.3m)
Total Stockholder Equity = 1.07b (last 4 quarters mean from totalStockholderEquity)
RoA = -22.89% (Net Income -311.4m / Total Assets 1.74b)
RoE = -29.08% (Net Income TTM -311.4m / Total Stockholder Equity 1.07b)
RoCE = -27.33% (EBIT -311.4m / Capital Employed (Equity 1.07b + L.T.Debt 68.5m))
RoIC = -27.29% (negative operating profit) (NOPAT -246.0m / Invested Capital 901.3m)
WACC = 11.92% (E(6.91b)/V(6.99b) * Re(12.06%) + D(82.3m)/V(6.99b) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 12.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.08%
[DCF] Fair Price = unknown (Cash Flow -234.3m)
EPS Correlation: -39.92 | EPS CAGR: -32.80% | SUE: -1.70 | # QB: 0
Revenue Correlation: -43.31 | Revenue CAGR: -27.64% | SUE: -1.19 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.89 | Chg7d=+0.040 | Chg30d=+0.100 | Revisions Net=+1 | Analysts=17
EPS current Year (2026-12-31): EPS=-3.56 | Chg7d=+0.079 | Chg30d=+0.210 | Revisions Net=-1 | Growth EPS=+3.4% | Growth Revenue=+6.9%
EPS next Year (2027-12-31): EPS=-4.01 | Chg7d=-0.194 | Chg30d=+0.049 | Revisions Net=+0 | Growth EPS=-12.4% | Growth Revenue=-1.4%
[Analyst] Revisions Ratio: +0.14 (4 Up / 3 Down within 30d for Next Quarter)
P/B = 7.6173
Revenue TTM = 39.2m USD
EBIT TTM = -311.4m USD
EBITDA TTM = -302.4m USD
Long Term Debt = 68.5m USD (estimated: total debt 82.3m - short term 13.8m)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 82.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -274.8m USD (from netDebt column, last quarter)
Enterprise Value = 6.14b USD (6.91b + Debt 82.3m - CCE 848.3m)
Interest Coverage Ratio = -897.3 (Ebit TTM -311.4m / Interest Expense TTM 347.0k)
EV/FCF = -26.21x (Enterprise Value 6.14b / FCF TTM -234.3m)
FCF Yield = -3.82% (FCF TTM -234.3m / Enterprise Value 6.14b)
FCF Margin = -597.8% (FCF TTM -234.3m / Revenue TTM 39.2m)
Net Margin = -794.4% (Net Income TTM -311.4m / Revenue TTM 39.2m)
Gross Margin = 94.78% ((Revenue TTM 39.2m - Cost of Revenue TTM 2.05m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.52 (Enterprise Value 6.14b / Total Assets 1.74b)
Interest Expense / Debt = 0.08% (Interest Expense 69.0k / Debt 82.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -246.0m (EBIT -311.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.47 (Total Current Assets 871.2m / Total Current Liabilities 83.2m)
Debt / Equity = 0.05 (Debt 82.3m / totalStockholderEquity, last quarter 1.58b)
Debt / EBITDA = 0.91 (negative EBITDA) (Net Debt -274.8m / EBITDA -302.4m)
Debt / FCF = 1.17 (negative FCF - burning cash) (Net Debt -274.8m / FCF TTM -234.3m)
Total Stockholder Equity = 1.07b (last 4 quarters mean from totalStockholderEquity)
RoA = -22.89% (Net Income -311.4m / Total Assets 1.74b)
RoE = -29.08% (Net Income TTM -311.4m / Total Stockholder Equity 1.07b)
RoCE = -27.33% (EBIT -311.4m / Capital Employed (Equity 1.07b + L.T.Debt 68.5m))
RoIC = -27.29% (negative operating profit) (NOPAT -246.0m / Invested Capital 901.3m)
WACC = 11.92% (E(6.91b)/V(6.99b) * Re(12.06%) + D(82.3m)/V(6.99b) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 12.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 20.08%
[DCF] Fair Price = unknown (Cash Flow -234.3m)
EPS Correlation: -39.92 | EPS CAGR: -32.80% | SUE: -1.70 | # QB: 0
Revenue Correlation: -43.31 | Revenue CAGR: -27.64% | SUE: -1.19 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.89 | Chg7d=+0.040 | Chg30d=+0.100 | Revisions Net=+1 | Analysts=17
EPS current Year (2026-12-31): EPS=-3.56 | Chg7d=+0.079 | Chg30d=+0.210 | Revisions Net=-1 | Growth EPS=+3.4% | Growth Revenue=+6.9%
EPS next Year (2027-12-31): EPS=-4.01 | Chg7d=-0.194 | Chg30d=+0.049 | Revisions Net=+0 | Growth EPS=-12.4% | Growth Revenue=-1.4%
[Analyst] Revisions Ratio: +0.14 (4 Up / 3 Down within 30d for Next Quarter)